Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Wynand, Smythe"'
Autor:
Dike B Ojji, Gabriel L Shedul, Mahmoud Sani, Okechukwu S Ogah, Anastase Dzudie, Felix Barasa, Charles Mondo, Prossie M Ingabire, Erika S W Jones, Brian Rayner, Damasceno Albertino, Elijah Ogola, Wynand Smythe, Nicky Hickman, Veronica Francis, Pandie Shahiemah, Grace Shedul, Akinyemi Aje, Karen Sliwa, Simon Stewart
Publikováno v:
American Journal of Hypertension. 35:551-560
Background We sought to address the paucity of data to support the evidence-based management of hypertension to achieve optimal blood pressure (BP) control on a sex-specific basis in Africa. Methods We undertook a post hoc analysis of the multicenter
Autor:
Dike B, Ojji, Victoria, Cornelius, Giles, Partington, Veronica, Francis, Shahiemah, Pandie, Wynand, Smythe, Nicky, Hickman, Felix, Barasa, Albertino, Damasceno, Anastase, Dzudie, Erika, Jones, Prossie Merab, Ingabire, Charles, Mondo, Okechukwu, Ogah, Elijah, Ogola, Mahmoud U, Sani, Gabriel Lamkur, Shedul, Grace, Shedul, Brian, Rayner, Karen, Sliwa, Neil, Poulter
Publikováno v:
Hypertension (Dallas, Tex. : 1979). 79(11)
Background: The effect of 3 commonly recommended combinations of anti-hypertensive agents—amlodipine plus hydrochlorothiazide (calcium channel blocker [CCB]+thiazide), amlodipine plus perindopril (CCB+ACE [angiotensin-converting enzyme]-inhibitor),
Autor:
Ismaeel Ebrahim, Helen McIlleron, Catherine Orrell, Gary Maartens, Wynand Smythe, Lubbe Wiesner
Publikováno v:
J Antimicrob Chemother
Background Darunavir/ritonavir is better tolerated than lopinavir/ritonavir and has a higher genetic barrier to resistance. Co-administration with rifampicin has been contraindicated as a significant reduction in darunavir exposure is expected. This
Autor:
Dike B, Ojji, Bongani, Mayosi, Veronica, Francis, Motasim, Badri, Victoria, Cornelius, Wynand, Smythe, Nicky, Kramer, Felix, Barasa, Albertino, Damasceno, Anastase, Dzudie, Erika, Jones, Charles, Mondo, Okechukwu, Ogah, Elijah, Ogola, Mahmoud U, Sani, Gabriel L, Shedul, Grace, Shedul, Brian, Rayner, Ikechi G, Okpechi, Karen, Sliwa, Neil, Poulter, K, Sliwa
Publikováno v:
New England Journal of Medicine. 380:2429-2439
BACKGROUND The prevalence of hypertension among black African patients is high, and these patients usually need two or more medications for blood-pressure control. However, the most effective two-drug combination that is currently available for blood
Autor:
Jotam G. Pasipanodya, Gesham Magombedze, Corinne Merle, Tawanda Gumbo, Wynand Smythe, Devyani Deshpande, Piero Olliaro, Helen McIlleron
Publikováno v:
Clinical Infectious Diseases. 67:S284-S292
BackgroundIn the experimental arm of the OFLOTUB trial, gatifloxacin replaced ethambutol in the standard 4-month regimen for drug-susceptible pulmonary tuberculosis. The study included a nested pharmacokinetic (PK) study. We sought to determine if PK
Autor:
B Wright, Nicky Kramer, Richard Court, Maxwell Chirehwa, Wynand Smythe, Lubbe Wiesner, Helen McIlleron
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 22:537-543
Setting Rifampicin (RMP) drives treatment response in drug-susceptible tuberculosis. Low RMP concentrations increase the risk of poor outcomes, and drug quality needs to be excluded as a contributor to low RMP exposure. Objectives and design We perfo
Autor:
Jotam G. Pasipanodya, Tawanda Gumbo, Thearith Koeuth, Shashikant Srivastava, Wynand Smythe, Paula Bendet, Paul G. Ambrose, Armand Van Deun, M Gumusboga, Helen McIlleron, Sujata M. Bhavnani, Guy E. Thwaites, Devyani Deshpande
Background Gatifloxacin is used for the treatment of multidrug-resistant tuberculosis (MDR-TB). The optimal dose is unknown. Methods We performed a 28-day gatifloxacin hollow-fiber system model of tuberculosis (HFS-TB) study in order to identify the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90f1e5750b0aeefcab9ba8ef4c7a27c3
https://europepmc.org/articles/PMC6904296/
https://europepmc.org/articles/PMC6904296/
Autor:
Nicky Kramer, Wynand Smythe
This chapter serves as a quick guide for the practical management of Investigational Medicinal Product (IMP) in clinical trials, which forms an integral aspect of clinical trial management. Clinical trials evaluating IMP require stringent controls of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59e9dbd733cdf4b880c67e8628cae176
https://doi.org/10.1016/b978-0-12-804729-3.00011-0
https://doi.org/10.1016/b978-0-12-804729-3.00011-0
Autor:
Christian Lienhardt, Mame Bocar Lo, Helen McIlleron, Wynand Smythe, Piero Olliaro, John R. Horton, Oumou Bah-Sow, M. Gninafon, Ulrika S. H. Simonsson, Roxana Rustomjee, Pete Smith, Corinne Merle
A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculosis in a phase 3 randomized controlled trial (OFLOTUB). A prior single-dose study found that gatifloxacin exposure increased
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d20a0d478214e31fa22f4aacef87cb7d